Valentine’s breakup for ASAX’s SPAC Deal with HotelPlanner and Reservations.com

by | Feb 14, 2022

ASAX proves breaking up doesn’t have to be hard to do. Valentine’s day proves to be a day of unrequited love for Astrea Acquisition Corp. (ASAX), which terminated its merger with HotelPlanner and Reservations.com. SPAC shareholders were scheduled to vote on the transaction tomorrow, but appear to have been spooked by the extraordinarily high redemptions (over 90%). Note that the deal didn’t include PIPE financing. Today’s ASAX news comes on the heels of the announcement last week that ASAX is an entirely different company from recently de-SPAC’d Astra Space (ASTR), whose shares plummeted over 40%.

High redemptions are thwarting deals. As we’ve seen in recent weeks, the high rate of redemptions isa recurring theme which is preventing deals from getting done.  Redemptions have steadily increased over the past three consecutive months.

ASAX still has almost a year to give a deal another try—but…. ASAX’s mandate to combine with a target in hospitality or fintech may prove difficult to execute in the current macro. Notably, Fertitta Entertainmentand FAST Acquisition Corp (FST called off their $8.6 billion merger in December.  Short-term rental specialist Sonder (SOND), which came public via Gores Metropoulos II (GMII) last month, is the latest hospitality SPAC to hit the market. Shares closed Friday at $9.00.

Surprising some, ASAX shares are up ~17% intraday.

The continued slide in SPAC warrant prices underscores the growing SPAC merger concerns. Prices have been on the slide for over a year and continue to search for a bottom.

<a href="https://www.boardroomalpha.com/author/joanna/" target="_self">Joanna Makris</a>

Joanna Makris

Joanna has been analyzing and investing in emerging technologies for over two decades, having led the Technology, Media, and Telecom research at several global investment banks, including Mizuho Securities and Canaccord Genuity. Navigating stock market volatility since it all began in 2000. Banjo player, artist, and frittata-maker.

Know Who Drives Return

Objective, data-driven assessments for every public company director and officer.

SPAC Analytics & Database

Comprehensive research and analytics on every SPAC, sponsor, and deal. Real-time alerts, yields, red flags, filings, investors, and much more. API access to institutional grade SPAC database.

Monthly SPAC Review

SPAC Market Review – December 2021

2021 is drawing to a close and what a year it was for SPACs. In our December market update we take a look at the last month of the year and give our latest thoughts on the market, including: record IPO issuance and SPAC supply; aging SPACs and outlook for terminations; and the merger market including its financing evolution

SPAC Research & Analysis

Moroccan Agribusiness Forafric debuts

Moroccan agribusiness Forafric (AFRI) debuts. With TCAC / Springbig approved at 96% redemptions, we take a look at redemption trends. Lots of extension votes coming up. And the rest of the day’s news in SPACs.

Warehouse Robot Maker Symbotic Gets Juiced

Shares of warehouse robot maker Symbotic (SYM) join the high redemption/thin float club, popping 120% on today’s debut. Merger approval for DYNS/ Senti Bio. The usual extensions. And the rest of the day’s news in SPACs.

SVFC / Symbotic Approved

SVFC approves Symbotic merger. SPACs are busy with 4 merger votes this week. Fingers crossed…lots of extension votes. And the rest of the day’s news in SPACs.

Know Who Drives Return Podcast

Boardroom Alpha Daily Read

We take a look at the day’s news, ESG trends and special situations. Management shakeup at Faraday Future (FIFE) is an all-too familiar story in the world of EV SPACs. Blackrock to be 75% net-zero aligned by 2030, and Jana closing in (again) at Treehouse Foods (THS).

FOXO Technologies CEO Jon Sabes Is About to Disrupt the Insurance Industry

Boardroom Alpha talks to Jon Sabes, CEO of FOXO Technologies, which announced a SPAC merger with sponsor Delwinds Insurance Acquisition Corp. (DWIN). Sabes explains how epigenetic biomarkers can change the game for life insurance companies and tell us more about health and wellness than ever before.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.